BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a business update.

Thermo Fisher Scientific, the world leader in serving science, today introduced two breakthrough imaging filters, the Thermo Scientific Selectris Imaging Filter and the Thermo Scientific Selectris X Imaging Filter, taking cryo-electron microscopy (cryo-EM)

DexCom, Inc. announced that management will present an update on Dexcom

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business progress.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half financial results for 2020.

Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, announced that its 2020 Annual Meeting of Stockholders that convened on August 7, 2020 has been adjourned until September 4, 2020 at 2:00 p.m. Eastern Time

Novocellbio Co., Ltd. conducted experiments using “NOVO-NK”, an autologous natural killer cell treatment at Seoul National University College of Medicine. It was confirmed that the autologous natural killer cell treatment agent NOVO-NK killed the human-derived COVID-19 coronavirus.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.

Announced Path Forward for VS-6766 and Defactinib Combination Following Meeting with FDA Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Company Monetizes COPIKTRA ® (duvelisib) Providing Cash Runway Until at Least 2024 BOSTON--( BUSINESS WIRE )-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutic

Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Interim Analysis Results for Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia Expected in September 2020 Topline Data for RELIEF Trial Expected in Fourth Quarter 2020